HK1207828A1 - Cell-derived viral vaccines with low levels of residual cell dna dna - Google Patents

Cell-derived viral vaccines with low levels of residual cell dna dna

Info

Publication number
HK1207828A1
HK1207828A1 HK15108523.2A HK15108523A HK1207828A1 HK 1207828 A1 HK1207828 A1 HK 1207828A1 HK 15108523 A HK15108523 A HK 15108523A HK 1207828 A1 HK1207828 A1 HK 1207828A1
Authority
HK
Hong Kong
Prior art keywords
dna
cell
cell culture
low levels
residual
Prior art date
Application number
HK15108523.2A
Other languages
English (en)
Chinese (zh)
Inventor
Holger Kost
Jens-Peter Gregersen
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1207828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1207828A1 publication Critical patent/HK1207828A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15108523.2A 2005-11-01 2015-09-01 Cell-derived viral vaccines with low levels of residual cell dna dna HK1207828A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
HK1207828A1 true HK1207828A1 (en) 2016-02-12

Family

ID=37969762

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09107245.9A HK1129837A1 (en) 2005-11-01 2009-08-07 Cell-derived viral vaccines with low levels of residual cell dna - dna
HK15108523.2A HK1207828A1 (en) 2005-11-01 2015-09-01 Cell-derived viral vaccines with low levels of residual cell dna dna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09107245.9A HK1129837A1 (en) 2005-11-01 2009-08-07 Cell-derived viral vaccines with low levels of residual cell dna - dna

Country Status (19)

Country Link
US (2) US10655108B2 (xx)
EP (3) EP1951296B2 (xx)
JP (5) JP5602366B2 (xx)
KR (1) KR20080081254A (xx)
CN (2) CN104474543A (xx)
AT (1) ATE494906T1 (xx)
AU (2) AU2006310171B2 (xx)
CA (1) CA2627971A1 (xx)
CY (1) CY1111378T1 (xx)
DE (1) DE602006019629D1 (xx)
DK (1) DK1951296T4 (xx)
EA (1) EA014062B1 (xx)
ES (2) ES2525518T3 (xx)
HK (2) HK1129837A1 (xx)
NZ (1) NZ567817A (xx)
PL (2) PL1951296T5 (xx)
PT (1) PT2301572E (xx)
SI (1) SI1951296T2 (xx)
WO (1) WO2007052163A2 (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474543A (zh) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
CN102597246B (zh) 2009-05-21 2014-02-26 诺华股份有限公司 使用非内源pol I启动子的反向遗传
EP2459722B1 (en) 2009-07-31 2017-09-06 Seqirus UK Limited Reverse genetics systems
CN102648003B (zh) 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
CN102946727B (zh) * 2010-05-06 2015-08-19 诺华有限公司 微生物灭活的有机过氧化物化合物
CA2800150C (en) 2010-05-21 2018-09-04 Novartis Ag Influenza virus reassortment method
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
DK2575872T3 (da) 2010-06-01 2020-10-19 Seqirus Uk Ltd Koncentrering af influenzavaccineantigener uden frysetørring
EP2603234B1 (en) 2010-08-12 2017-06-28 Yisheng Biopharma Holdings Ltd. Method for reducing dna impurities in viral compositions
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
EP2678452B1 (en) 2011-02-25 2016-02-24 Novartis AG Exogenous internal positive control for virus detection
WO2013098655A2 (en) * 2011-11-03 2013-07-04 Sentinext Therapeutics Sdn Bhd Antigens and vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
JP2015526062A (ja) 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
MX2015011529A (es) 2013-03-13 2016-02-05 Novartis Ag Reordenamiento del virus de infuenza b.
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
CN106661102B (zh) * 2014-05-28 2021-01-26 财团法人卫生研究院 作为对抗肠病毒感染之免疫原的病毒颗粒及其制造
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
EP3764098B1 (en) 2015-07-07 2022-11-16 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
EP4316515A4 (en) * 2021-03-30 2024-09-25 Denka Company Ltd FLU VACCINE
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (xx) * 1974-01-14 1977-07-15 Sandoz Ag
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
ES2061500T5 (es) 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (ja) 1991-09-25 2000-11-13 松下電工株式会社 多重伝送システムの割込処理方法
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1999062546A1 (en) * 1998-06-01 1999-12-09 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
HUP0202846A3 (en) 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001041814A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
AU2002254558A1 (en) 2001-04-27 2002-11-11 Becton, Dickinson And Company Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DK1499348T3 (en) 2002-04-26 2015-01-05 Medimmune Llc PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE
AU2003299244A1 (en) 2002-12-20 2004-07-14 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
US20060257852A1 (en) * 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
BRPI0410702B1 (pt) 2003-05-28 2022-04-12 Wisconsin Alumni Research Foundation Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
EP1747268A1 (en) 2004-05-20 2007-01-31 ID Biomedical Corporation Process for the production of an influenza vaccine
WO2006027698A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Decreasing potential iatrogenic risks associated with influenza vaccines
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
KR101323459B1 (ko) 2004-12-23 2013-10-29 메디뮨 엘엘씨 바이러스의 증식을 위한 비종양형성성 ｍｄｃｋ 세포주
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN104474543A (zh) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
SG174813A1 (en) * 2006-09-15 2011-10-28 Medimmune Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same

Also Published As

Publication number Publication date
BRPI0618094A2 (pt) 2011-08-16
AU2011201968B2 (en) 2014-08-28
HK1129837A1 (en) 2009-12-11
WO2007052163A3 (en) 2007-09-07
US10655108B2 (en) 2020-05-19
JP2016185988A (ja) 2016-10-27
AU2006310171B2 (en) 2011-02-17
DE602006019629D1 (de) 2011-02-24
JP6639077B2 (ja) 2020-02-05
JP2014198726A (ja) 2014-10-23
JP2011256209A (ja) 2011-12-22
US20200377864A1 (en) 2020-12-03
AU2006310171A1 (en) 2007-05-10
US20090304729A1 (en) 2009-12-10
AU2011201968A1 (en) 2011-05-19
BRPI0618094A8 (pt) 2017-08-22
CN104474543A (zh) 2015-04-01
PL2301572T3 (pl) 2015-02-27
NZ567817A (en) 2012-01-12
EP1951296A2 (en) 2008-08-06
ES2359214T5 (es) 2014-10-08
DK1951296T3 (da) 2011-03-28
EP2301572B1 (en) 2014-09-10
ES2359214T3 (es) 2011-05-19
SI1951296T1 (sl) 2011-04-29
EA014062B1 (ru) 2010-08-30
JP7049761B2 (ja) 2022-04-07
KR20080081254A (ko) 2008-09-09
CA2627971A1 (en) 2007-05-10
EP1951296B1 (en) 2011-01-12
JP2020023557A (ja) 2020-02-13
ES2525518T3 (es) 2014-12-26
EP1951296B2 (en) 2014-07-23
JP5602366B2 (ja) 2014-10-08
PL1951296T3 (pl) 2011-09-30
PT2301572E (pt) 2014-12-22
EA200801221A1 (ru) 2008-10-30
CN101365480B (zh) 2014-11-05
DK1951296T4 (da) 2014-09-01
US11466257B2 (en) 2022-10-11
WO2007052163A2 (en) 2007-05-10
CN101365480A (zh) 2009-02-11
ATE494906T1 (de) 2011-01-15
PL1951296T5 (pl) 2015-06-30
EP2842572A1 (en) 2015-03-04
CY1111378T1 (el) 2015-08-05
EP2301572A1 (en) 2011-03-30
JP2009513694A (ja) 2009-04-02
SI1951296T2 (sl) 2014-09-30

Similar Documents

Publication Publication Date Title
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007024941A3 (en) Polyvalent vaccine
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
EP4368202A3 (en) Attenuated viruses useful for vaccines
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2004112831A3 (en) High titer recombinant influenza viruses for vaccines and gene therapy
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2006074303A3 (en) Delivery vehicles, bioactive substances and viral vaccines
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
EA201170533A1 (ru) Высокодиспергируемый диоксид кремния для резин и способ его получения
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2009080715A3 (en) Vaccines for malaria
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
WO2008124176A3 (en) Soluble and membrane-anchored forms of lassa virus subunit proteins
TW200531701A (en) Method of vaccination against testicular BVDV infection
WO2008002152A3 (en) Process for culturing bacteria of the piscirickettsia genus